Posted by Michael Wonder on 02 Apr 2024
BMS’ oral plaque psoriasis drug Sotyktu gets reimbursement starting April
1 April 2024 - Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate to severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chronic severe plaque psoriasis.
Sotyktu’s insurance benefits will be provided for adult patients 18 and older with chronic severe plaque psoriasis lasting at least six months.
